decitabine + GM-CSF + PD-1 inhibitor

This is a combination therapy consisting of three agents: - **Decitabine** is a hypomethylating agent (a DNA methyltransferase inhibitor) that induces epigenetic changes, leading to increased expression of tumor antigens and enhanced immune recognition. - **GM-CSF (Granulocyte-macrophage colony-stimulating factor)** is a cytokine that stimulates the production and activation of granulocytes and macrophages, enhancing antigen presentation and immune cell infiltration into tumors. - **PD-1 inhibitor** refers to monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) receptor on T cells, blocking its interaction with PD-L1/PD-L2 ligands on tumor or immune cells. This releases inhibitory signals on T cells, restoring their anti-tumor activity. The rationale for this combination is to use decitabine’s epigenetic modulation to increase tumor immunogenicity, GM-CSF’s ability to boost innate immunity and antigen presentation, and PD-1 inhibitors’ checkpoint blockade effect—together aiming for synergistic anti-tumor responses. This approach has been explored in various cancers including non-small cell lung cancer (NSCLC), relapsed/refractory classical Hodgkin lymphoma (cHL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and potentially other solid tumors[2][4][7]. Early clinical evidence suggests improved efficacy compared to single-agent therapies[2][4].